P097 ‘Real-world’ Janus kinase inhibitor treatments in the UK-Irish A-STAR register: cohort profile and treatment outcomes

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study2026
2. 2Comparative Safety Analysis of JAK Inhibitors in the Treatment of Atopic Dermatitis: Based on the FAERS Database2026
3. 3Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four <scp>JAK</scp> Inhibitors in Moderate‐To‐Severe Atopic Dermatitis2026 · 1 citations
4. 4P086 The UK-Irish Atopic Eczema Systemic TherApy Register (A-STAR): baseline characteristics of the cohort2024
5. 5AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis2026